13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
109 檔
20.1%
During the Q2 2024 filing period, Perceptive Advisors LLC (CIK: 0001224962) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $6.7B across 109 reported positions.
During Q2 2024, Perceptive Advisors LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 10.63% | — | — | |
| 2 | AM6 | Amicus Therapeutics Inc | Stock-Other | 6.70% | — | — | |
| 3 | ACLXGBX | Arcellx Inc | Stock-Other | 5.17% | — | -1.11% | |
| 4 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 5.01% | — | +34.56% | |
| 5 | NUVL | Nuvalent Inc-a | Stock-Other | 4.66% | -0.23% | -8.42% | |
| 6 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.41% | +0.28% | +5.45% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 3.39% | — | -3.63% | |
| 8 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.15% | — | +4.24% | |
| 9 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.83% | — | +62.64% | |
| 10 | ✓ | Immatics NV | Stock-Other | 2.26% | -0.42% | +76.46% | |
| 11 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.16% | -0.17% | EXIT | |
| 12 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.00% | +0.08% | +2.20% | |
| 13 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.79% | — | -38.46% | |
| 14 | AORT | Artivion Inc | Stock-Other | 1.73% | -0.58% | +4.67% | |
| 15 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.72% | +2.03% | +18.55% | |
| 16 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.59% | — | — | |
| 17 | EOLS | Evolus Inc | Stock-Other | 1.50% | +0.16% | — | |
| 18 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.50% | — | -26.94% | |
| 19 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.46% | — | +6.82% | |
| 20 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.42% | — | — | |
| 21 | NTRA | Natera Inc | Stock-Healthcare | 1.38% | +0.14% | NEW | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.35% | +0.01% | -30.67% | |
| 23 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 1.25% | — | — | |
| 24 | BHVN | Biohaven Ltd. | Stock-Other | 1.24% | — | -13.90% | |
| 25 | MGTX | MeiraGTx Holdings plc | Stock-Other | 1.15% | +0.44% | — | |
| 26 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.06% | -0.73% | +27.60% | |
| 27 | SLDB | Solid Biosciences Inc | Stock-Other | 0.94% | +0.11% | — | |
| 28 | CELC | Celcuity Inc | Stock-Other | 0.93% | -1.95% | — | |
| 29 | MDT | Medtronic plc | Stock-Healthcare | 0.93% | — | -65.68% | |
| 30 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.92% | — | -27.43% | |
| 31 | APLT | Applied Therapeutics Inc | Stock-Other | 0.90% | — | -5.88% | |
| 32 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.89% | -0.06% | -58.46% | |
| 33 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.86% | -4.08% | EXIT | |
| 34 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.85% | — | — | |
| 35 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.85% | — | -35.30% | |
| 36 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.85% | — | +8.10% | |
| 37 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.81% | -0.05% | -19.97% | |
| 38 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.75% | — | +78.23% | |
| 39 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.75% | -2.59% | -8.69% | |
| 40 | ADMA | Adma Biologics Inc | Stock-Healthcare | 0.75% | -0.07% | -56.93% | |
| 41 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.74% | — | -13.93% | |
| 42 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 0.74% | — | +7.94% | |
| 43 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.71% | -0.62% | — | |
| 44 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.66% | -0.01% | — | |
| 45 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.66% | -0.46% | -39.29% | |
| 46 | ARVN | Arvinas Inc | Stock-Other | 0.66% | — | -16.89% | |
| 47 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.65% | — | -30.79% | |
| 48 | IRON | Disc Medicine Inc | Stock-Other | 0.60% | — | -55.36% | |
| 49 | LIVN | LivaNova PLC | Stock-Other | 0.59% | — | +48.49% | |
| 50 | CGON | Cg Oncology Inc | Stock-Other | 0.56% | — | -43.74% |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 109 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CERE1EUR, AM6, ACLXGBX) accounted for 20.1% of total reported equity market value during Q2 2024.
During Q2 2024, Perceptive Advisors LLC's top holdings by market value included CERE1EUR (10.6%)、AM6 (6.7%)、ACLXGBX (5.2%). The largest single position, CERE1EUR, represented 10.6% of total portfolio value.
In Q2 2024, Perceptive Advisors LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.